Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Type 2 Diabetes Mellitus, Heart Failure, and Chronic Kidney Disease


Project Status:
Project Line:
Horizon Scan
Project Sub Line:
Environmental Scan
Project Number:
Effective finish date:

The class of sodium-glucose cotransporter 2 (SGLT2) inhibitors is an integral part of the management of type 2 diabetes. Recent published clinical evidence has provided further guidance on the role of SGLT2 inhibitors in type 2 diabetes, as well as other indications such as heart failure and chronic kidney disease. This Environmental Scan will assess the current reimbursement of the SGLT2 drug class relevant to public drug programs. The Environmental Scan will include the regulatory, exclusivity, CADTH Reimbursement Review, and reimbursement status of SGLT2 inhibitors for type 2 diabetes mellitus, heart failure, and chronic kidney disease.